Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDE | P14735 | 1/20 | 0.40 |
| ▸ | IL1RN | P18510 | 3/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13062085 | 0.90 | IL1RN (0.43) | IL1RNERAP2MAOBERAP1PTGS2 | |
| SCHEMBL3734511 | 0.89 | CA2 (0.51) | IL1RNERAP2ERAP1 | |
| SCHEMBL3734516 | 0.89 | CA2 (0.51) | IL1RNERAP2ERAP1 | |
| SCHEMBL13062319 | 0.87 | PTGS2 (0.39) | IL1RNERAP2ERAP1PTGS2CYP3A4 | |
| SCHEMBL13078268 | 0.86 | MAOB (0.40) | IDEMAOBCYP3A4MAPTAURKB | |
| SCHEMBL13062078 | 0.86 | PTGS2 (0.40) | IL1RNERAP2ERAP1PTGS2CYP3A4 | |
| SCHEMBL13062414 | 0.86 | PTGS2 (0.38) | IL1RNERAP2ERAP1PTGS2CYP3A4 | |
| SCHEMBL13062305 | 0.86 | PTGS2 (0.38) | IL1RNERAP2MAOBERAP1PTGS2 | |
| SCHEMBL10183089 | 0.84 | CYP3A4 (0.46) | IL1RNERAP2ERAP1PTGS2CYP3A4 | |
| SCHEMBL13062321 | 0.83 | PTGS2 (0.41) | MAOBPTGS2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7829063-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | CA9, CA4, CA13 | IDE 558/4885IL1RN 1995/4885ERAP2 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.